Sanara MedTech financials
$35.09−0.03%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $103.1M | $86.7M | $65.0M | $45.8M | $24.1M | $15.6M |
| Gross profit | $95.6M | $78.5M | $57.1M | $39.5M | $21.8M | $14.0M |
| Gross margin | 92.7% | 90.6% | 87.9% | 86.1% | 90.4% | 89.6% |
| Operating income | $7.3M | $1.3M | -$4.2M | -$12.5M | -$7.4M | -$5.0M |
| Net income | -$37.6M | -$9.7M | -$4.3M | -$7.9M | -$7.9M | -$4.4M |
| Net margin | −36.4% | −11.2% | −6.6% | −17.3% | −32.8% | −27.9% |
| Diluted EPS | $-4.36 | $-1.14 | $-0.52 | $-1.00 | $-1.08 | $-0.76 |
| EBITDA | $13.1M | $6.2M | -$4.0M | -$10.1M | -$6.8M | -$4.7M |
| Operating cash flow | $6.8M | -$23.8K | -$3.2M | -$5.6M | -$4.8M | -$4.0M |
| Free cash flow | $2.2M | -$229.6K | -$3.5M | -$5.7M | -$5.0M | -$4.6M |
| Diluted shares | 8.6M | 8.5M | 8.3M | 7.9M | 7.3M | 5.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $16.6M | $15.9M | $5.1M | $9.0M | $18.7M | $455.4K |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $46.5M | $31.9M | $11.6M | $0.00 | $0.00 | $0.00 |
| Total assets | $72.9M | $88.1M | $73.9M | $61.0M | $36.4M | $9.8M |
| Total liabilities | $67.0M | $49.2M | $29.3M | $19.3M | $6.2M | $4.0M |
| Shareholders' equity | $5.9M | $38.9M | $44.6M | $41.7M | $30.2M | $5.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology